Kamada's fundraising effort continues
The company has signed agreements with ten investors for a private placement of NIS 39.45 million.
Erez Wollberg, Globes[online] (18 May 09

Biopharmaceutical drug development company Kamada Ltd. (TASE: KMDA) is continuing to raise capital. Yesterday, the company signed agreements with ten investors, including three institutional investors, for a private placement of NIS 39.45 million.


Kamada raises further NIS 6 million
The latest investment follows the $7 million that the company raised last week.
Gali Weinreb, Globes[online] (10 May 09)

Biopharmaceutical company Kamada Ltd. (TASE:KMDA) today announced that it had expanded its latest round of fund raising with a NIS 6 million investment from Meitav Provident and Pension Fund Ltd. and from Meitav Mishan Provident Fund Management Ltd.


Kamada completes NIS 29 million funding
The news comes two months after a reported agreement was signed for the investment. Gali Weinreb, Globes[online] (3 May 09)

Biopharmaceutical company Kamada Ltd. (TASE:KMDA) has raised NIS 29 million from its founder Ralph Hahn and investment group UDT Med Holdings. The news comes two months after a reported agreement was signed for the investment. Kamada reported that it will continue to seek additional investment funds. The company recently completed Phase III clinical trials for hereditary AAT deficiency, and Phase II trials for a treatment of cystic fibrosis.